<DOC>
	<DOCNO>NCT02160678</DOCNO>
	<brief_summary>To compare safety efficacy profile Tazarotene Cream , 0.1 % reference list drug Tazorac® ( tazarotene ) Cream , 0.1 % order demonstrate bioequivalence , demonstrate superiority 2 active cream cream vehicle ( placebo ) treatment acne vulgaris .</brief_summary>
	<brief_title>Generic Tazarotene Cream , 0.1 % Treatment Acne Vulgaris</brief_title>
	<detailed_description>This randomize , placebo-controlled , parallel-group , multicenter , double-blind study Tazarotene Cream , 0.1 % subject acne vulgaris . Subjects assign 1:1:1 ratio test product , reference product , cream vehicle . Subjects admit study write informed consent obtain inclusion none exclusion criterion meet . Randomized subject apply study medication daily even 12 week ( 84 day ) .</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Tazarotene</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>1 . Be willing able provide write informed consent/assent study . 2 . Be healthy male nonpregnant female age ≥ 12 ≤ 40 year age , inclusive . 3 . Have clinical diagnosis acne vulgaris , define follow : 1 . On face , ≥ 20 inflammatory lesion ( papule pustule ) 2 . On face , ≥ 25 noninflammatory lesion ( open close comedo ) 3 . On face , ≤ 2 nodulocystic lesion ( nodule cyst ) 4 . Baseline IGA acne severity grade 2 , 3 , 4 4 . Be general good health free clinically significant disease acne vulgaris might interfere study evaluation . 5 . Be willing refrain use topical acne medication antibiotics 12week treatment period . 6 . Be willing able understand comply requirement study , apply study medication instruct , return require treatment period visit , comply therapy prohibition , able complete study . 7 . Female subject childbearing potential ( exclude woman surgically sterilize postmenopausal least 2 year ) must negative urine pregnancy test ( minimum sensitivity least 50 mIU/mL human chorionic gonadotropin [ hCG ] , begin treatment normal menstrual period must agree use medically accept method contraception study . The following consider acceptable method birth control purpose study : oral contraceptive , contraceptive patch , contraceptive implant , vaginal contraceptive , double barrier method ( e.g. , condom spermicide ) , contraceptive injection ( DepoProvera® ) , intrauterine device ( IUD ) , hormonal IUD ( Mirena® ) , abstinence document second acceptable method birth control subject become sexually active . Subjects enter study hormonal contraceptive must method least 90 day prior study continue method duration study . Subjects use hormonal contraception stop must stop less 90 day prior Visit 1/Day 1 . 8 . Be willing limit sun exposure overall , maintain reasonably constant exposure , avoid use tan booth UV light source participation study . 1 . Females pregnant , breast feeding , plan pregnancy , agree use acceptable form birth control study . 2 . Presence skin condition would interfere diagnosis assessment acne vulgaris ( e.g. , face : rosacea , dermatitis , psoriasis , squamous cell carcinoma , eczema , acneiform eruption cause medication , steroid acne , steroid folliculitis , bacterial folliculitis ) . 3 . Currently active cystic acne , acne conglobata , acne fulminans , secondary acne , severe acne require topical treatment . 4 . Currently facial sunburn . 5 . Received initial administration estrogens oral contraceptive &lt; 3 month ( 90 day ) prior baseline ( Visit 1/Day 1 ) , discontinue estrogens oral contraceptive &lt; 3 month ( 90 day ) prior baseline . Use therapy must remain constant study . 6 . Use treatment list Table 8.1 recently indicate washout period prior baseline ( Visit 1/Day 1 ) . 7 . Need intent continue use treatment list Table 8.1 current study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>